Lipocine Inc (LPCN) Stock Price, Quote & News

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the ma...

Industry: Biotechnology

Sector: Healthcare

Phone: 801 994 7383

Fax: 801 994 7388

Website: www.lipocine.com

Address:

675 Arapeen Drive, Suite 202, Salt Lake City, United States

ShodAchiever Apr. 8 at 10:25 AM

$LPCN dropped a staggering 80% on April 2. I like gap downs because my overall strat has paid off ever since the past. Insider acquisitions right after the drop has increased my confidence even thought LPCN1154 has not shown statistically significant results. I am long on the technicals and considering heavy ownership by institutions like Blackrock, Vanguard etc. Earnings call: May 7 Support at 2. TP levels: The major EMAs (20, 50 & 200) all the way to fill the gap on the daily. Strat is to scale out. I am not a financial advisor and this is not financial advise. I am only sharing my own personal opinion, thoughts, plans and strategy. Manage your risk!

1 · Reply

Tanner_charting Apr. 8 at 10:19 AM

$PARR $TGB $LPCN $SIMO pop

0 · Reply

husmann Apr. 8 at 5:36 AM

$LPCN Maybe they have a plan for a buyout ?

0 · Reply

BigBenBroke Apr. 8 at 2:57 AM

$LPCN what’s the transaction code P stand for ?

1 · Reply

DrKyle Apr. 7 at 11:21 PM

$LPCN these insiders buying already know the value of any exit plan...just in case that wasnt obvious for all here

0 · Reply

PLATINUM_TRADES Apr. 7 at 10:45 PM

$LPCN Should bounce soon.. Stay with me I'll get u in when it's ready 🤔

2 · Reply

DivvyDoo Apr. 7 at 10:40 PM

$LPCN 40k more for Higuchi https://www.sec.gov/Archives/edgar/data/1535955/000149315226015583/xslF345X06/ownership.xml

0 · Reply

DrKyle Apr. 7 at 7:57 PM

$LPCN hmmmm which insiders bought today? PRINCIPAL ACCOUNTING OFFICER? CHIEF MEDICAL DIRECTOR? VP PRODUCT DEVELOPMENT? HIGUCHI? JENE? ONO? Papapetropoulos? We'll find out shortly after a word from our sponsors

1 · Reply

BBELLii Apr. 7 at 2:50 PM

$LPCN ✅🚀🚀🚀

1 · Reply

TradeOrGoHome Apr. 7 at 1:44 PM

$LPCN 2.07 rejected which is fine. Time will come. Scooping more shares if it gets below 1.94. Holding 5000 so far.

0 · Reply

What's Going On With Lipocine Stock On Monday?

Apr 6, 2026, 7:56 AM EDT - 2 days ago

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Apr 2, 2026, 10:58 AM EDT - 5 days ago

Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint

Apr 2, 2026, 8:00 AM EDT - 6 days ago

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Mar 10, 2026, 8:00 AM EDT - 4 weeks ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Feb 18, 2026, 8:00 AM EST - 7 weeks ago

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Jan 20, 2026, 8:00 AM EST - 2 months ago

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Jan 12, 2026, 8:00 AM EST - 3 months ago

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Dec 16, 2025, 8:00 AM EST - 4 months ago

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Nov 18, 2025, 8:00 AM EST - 5 months ago

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Nov 6, 2025, 8:00 AM EST - 5 months ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Nov 4, 2025, 8:00 AM EST - 5 months ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Sep 30, 2025, 8:00 AM EDT - 6 months ago

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Sep 5, 2025, 4:30 PM EDT - 7 months ago

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 8:00 AM EDT - 8 months ago

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Aug 5, 2025, 8:00 AM EDT - 8 months ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Jun 26, 2025, 8:00 AM EDT - 10 months ago

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Jun 23, 2025, 8:00 AM EDT - 10 months ago

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Jun 9, 2025, 8:00 AM EDT - 10 months ago

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

May 22, 2025, 8:00 AM EDT - 11 months ago

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 14, 2025, 8:00 AM EDT - 11 months ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 8, 2025, 8:00 AM EDT - 11 months ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces FDA Labeling Changes for Testosterone Products

Feb 6, 2025, 8:00 AM EST - 1 year ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Dec 17, 2024, 8:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Nov 18, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 1, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Mar 7, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Mar 6, 2024, 8:00 AM EST - 2 years ago

Lipocine to Present at 36th Annual Roth Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Feb 2, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

ShodAchiever Apr. 8 at 10:25 AM

1 · Reply

Tanner_charting Apr. 8 at 10:19 AM

$PARR $TGB $LPCN $SIMO pop

0 · Reply

husmann Apr. 8 at 5:36 AM

$LPCN Maybe they have a plan for a buyout ?

0 · Reply

BigBenBroke Apr. 8 at 2:57 AM

$LPCN what’s the transaction code P stand for ?

1 · Reply

DrKyle Apr. 7 at 11:21 PM

$LPCN these insiders buying already know the value of any exit plan...just in case that wasnt obvious for all here

0 · Reply

PLATINUM_TRADES Apr. 7 at 10:45 PM

$LPCN Should bounce soon.. Stay with me I'll get u in when it's ready 🤔

2 · Reply

DivvyDoo Apr. 7 at 10:40 PM

$LPCN 40k more for Higuchi https://www.sec.gov/Archives/edgar/data/1535955/000149315226015583/xslF345X06/ownership.xml

0 · Reply

DrKyle Apr. 7 at 7:57 PM

1 · Reply

BBELLii Apr. 7 at 2:50 PM

$LPCN ✅🚀🚀🚀

1 · Reply

TradeOrGoHome Apr. 7 at 1:44 PM

$LPCN 2.07 rejected which is fine. Time will come. Scooping more shares if it gets below 1.94. Holding 5000 so far.

0 · Reply

DrKyle Apr. 7 at 12:15 PM

$LPCN hmmm insider buys came in as expected

1 · Reply

HoHoHoHum Apr. 7 at 10:32 AM

$LPCN Higuchi buy is very significant. He is a scientist with deep knowledge of the inner workings of the lipocine science. It is under his advisorship Patel completed his Ph.D. at the university of Utah.

0 · Reply

BioRich Apr. 7 at 4:52 AM

$LPCN Love the insider buys here. I don't blame them though. They were just gifted a ridiculous Share Price (and opportunity), and so were we. Should be fun tomorrow. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

0 · Reply